Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Teva's Igalmi Approved for At-Home Use to Treat Patients With Agitation Due to Mental Disorders

Teva's Igalmi Approved for At-Home Use to Treat Patients With Agitation Due to Mental Disorders

MT newswireMT newswire2026/11/16 13:21
09:21 AM EST, 11/16/2026 (MT Newswires) -- Teva Pharmaceutical Industries' (TEVA) Teva Pharmaceuticals US affiliate said Monday that the US Food and Drug Administration has approved at-home use of Igalmi sublingual film to treat agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorders in adults. The company said the approval makes Igalmi the first FDA-approved treatment for the disorders that can be used at home. Agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorders affects 25% to 40% of patients with those conditions, Teva said, adding that up to 21% of cases can result in an emergency department visit or hospitalization. Teva owns Igalmi as part of its October acquisition of BioXcel Therapeutics' assets.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix

According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.

华尔街见闻•2026/11/21 03:16

"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."

Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.

华尔街见闻•2026/11/21 02:16